门冬胰岛素30联合二甲双胍治疗T2DM的临床疗效及对患者血糖及血脂水平影响的研究

The Clinical Efficacy of Portal Insulin Aspartate 30 Combined with Metformin in the Treatment of T2DM and Its Effect on Patients' Blood Glucose Control Level and Blood Lipid Level

目的探讨和分析门冬胰岛素30联合二甲双胍治疗T2DM的临床疗效及对患者血糖和血脂水平的影响。方法选取2015年1月至2017年12月期间于我院接受治疗的104例T2DM患者作为此次研究对象,在患者知情并自愿参与的原则下,双盲法随机分为对照组(52例)和研究组(52例)。其中对照组给予二甲双胍治疗,研究组在此基础上再联合门冬胰岛素30治疗,持续治疗12w后,对两组患者血糖、血脂水平及生存质量(QOL-BRE)进行对比分析。结果治疗后,两组患者FPG、2h PG和Hb A1c水平较治疗前均呈显著性下降(P<0.05),且研究组下降水平与对照组相比,差异具有统计学意义(P<0.05);与治疗前相比,治疗后两组患者的TC、TG和LDL-C下降,HDL-C上升,差异具有统计学意义(P<0.05),且治疗后研究组血脂水平较对照组,差异同样具有统计学意义(P<0.05);两组患者治疗后的QOL-BREF评分均显著高于治疗前(P<0.05),且研究组QOL-BREF评分较对照组,差异具有显著性差异(P<0.05)。结论门冬胰岛素30联合二甲双胍治疗T2DM能显著控制血糖、血脂水平,并提升患者生存质量,是一种值得推荐的临床联合用药方案。

Objective To explore and analyze the effect of portal insulin aspartate 30 combined with metformin in the treatment of T2 DMand its effect on the levels of blood glucose control and blood lipid. Methods From January 2015 to December 2017,104 patients with T2 DMwho received treatment in our hospital were selected as the study subjects. With the informed consent and based on voluntary participation,the patients were randomly divided into the control group and the study group,with each group has 52 cases. The control group patients were given metformin treatment. In addition,the study group patients were given insulin aspartate 30 as well. After continuous treatment for 12 w,the patients＇ blood glucose,blood lipid control levels and the quality of life（QOL-BRE） results were compared between the two groups. Results After treatment,the levels of FPG,2 h PG and Hb A1 c in the two groups were significantly lower than those of before the treatment（P〈0. 05）,and more significantly in the study group than the control group（P〈0. 05）; Compared with before treatment,both groups of patients had TC,TG and LDL-C decreased significantly,HDL-C increased significantly after treatment（P〈0. 05）,and the study group had more significant index changes compared with the control group（P〈0. 05）; After treatment,the QOL-BREF scores for both groups were significantly higher than before treatment（P〈0. 05）,and more significant in the study group compared with the control group（P〈0. 05）. Conclusion Insulin aspartate 30 combined with metformin in the treatment of T2 DMcan reduce insulin resistance and repair the function of beta cells,also control the blood sugar and blood lipid levels,and improve the quality of life of patients,which is a recommendable clinical combined regimen.